-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $50

Benzinga·11/11/2026 15:22:08
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $56 to $50.